‘There’s a huge percentage of the US population that isn’t getting access to these medications’: Novo Nordisk makes game-changing $2 billion deal for new obesity drug

Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed a $2 billion deal to acquire the global rights to an experimental obesity treatment from China’s United Bio-Technology (Hengqin) Co. The March 24 agreement includes milestone payments of up to $1.8 billion, plus tiered royalties. The […]